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1SD – standard deviation 
2CR – complete response 
Conclusions: CT imaging allows detection of uterine 
perforation, as well as sub-serosal insertion of uterine 
tandem in CT-guided intracavitary HDR brachytherapy for 
cervix carcinoma. We report a relatively low incidence of 
these events, even without image guidance during applicators 
insertion. 
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Purpose/Objective: In brachytherapy, cervical tumors with 
large width and laterally asymmetrical geometry are difficult 
to treat with intracavitary applicators only. Combined 
intracavitary/interstitial applicators can optimize the 
possible dose distributions. This work proposes the use of a 
commercial available applicator in a modified way for better 
tumor coverage. 
Materials and Methods: A 70-year-old patient with stage IIB 
cervical cancer was treated with 50.4 Gy in 28 fractions 
external beam whole pelvic radiotherapy, additional 
brachytherapy with a planning aim of HR CTV D90 > 90 Gy 
EQD2 and HR CTV D98 > 80 Gy EQD2 in 4 fractions. An ovoid 
with holes drilled for guiding needle insertion was used 
(Utrecht applicator, Elekta Brachytherapy). The first 
insertion was done by conventional ovoids/needles position. 
In the second insertion, one ovoid was rotated, not fixed to 
the tandem and fixation mechanics, the needles were 
inserted more laterally to improve tumor coverage. 
Results: In MRI, the HR CTV maximum width was 4.1 cm, 3.5 
cm right-sided and 0.6 cm left-sided from the tandem. HR 
CTV volume was 49 cm3. With the rotating ovoid technique, 
the position of needles at level of tumor maximum width was 
0.5 cm shifted to right lateral side. And these resulted an 
improvement of D90 dose from 7.1 to 7.7 Gy and D98 dose 
from 5.8 to 6.3 Gy while decreasing doses to bladder and 
sigmoid. 
Conclusions: The novel technique of rotating ovoid-guided 
needles insertion was feasible and resulted improvement of 
dose coverage to tumor with remarkably laterally asymmetric 
geometry, and additionally diminish doses to surrounding 
normal organs. 
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Purpose/Objective: Cervical cancer is third most common 
female cancer and the fourth most common cause of cancer 
death. Combination of external beam radiation therapy 
(EBRT) with concomitant chemotherapy (CT) and 
brachytherapy (BT) is an essential treatment modality for this 
pathology. In intracavitary (IC) BT, an applicator is placed in 
uterine cavity and vaginal fornices. The accurate positioning 
of the IC applicator is of extreme importance for delivering 
the appropriate dose to the target volume, while keeping the 
surrounding tissues and organs with doses below their 
tolerance limits. Uterine perforation can lead to under 
dosage of the target volume and excessive dosage in the 
organs at risk, compromising local control of the disease and 
increasing the risk of acute and long-term complications. 
The aim of this work is to determine the incidence and 
characteristics of uterine perforation since the introduction 
of the 3D image-guided BT and its impact on the treatment of 
patients with cervical cancer. 
Materials and Methods: It was performed a retrospective 
analysis of clinical and radiological process of patients with 
cervical cancer treated with utero-vaginal image guided BT, 
between October/2011 and October/2104. 
Results: Between October/2011 and October/2014, 163 
patients underwent utero-vaginal BT with curative intent, 
314 applications were made. In all patients the treatment 
plan included EBRT (40 to 50 Gy) with concomitant CT. 
Uterine perforation occurred in 23 patients (14.1%) and in 27 
applications (8.6%). The most common site of perforation was 
the uterine fundus, followed by the anterior and posterior 
wall. All patients were treated conservatively without 
complications. The treatment was feasible in 13 patients who 
had uterine perforation. In patients who suffered uterine 
perforation, the average diagnosis age was 55 years old (30 to 
74 years old) and the average size of the cervix at diagnosis 
was 5 cm (3 to 7 cm). Six of these patients were submitted to 
previous cone biopsy and only 5 patients had retroflexed 
uterus. 
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Conclusions: 3D image-guided BT allows accurate 
identification of uterine perforations, preventing potential 
acute and long term complications, while ensuring that the 
appropriated dose is delivered to the target volume. 
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Purpose/Objective: Compare the dosimetry for plans 
generated by using the GEC –ESTRO guidelines with a 
traditional point A prescription in terms of tumourcoverage 
and dose to the OARs. 
Materials and Methods: The plans of 30 patients with 
cervical cancerwere reviewed, they all received EBRT to 
45Gy in 25 fractions with concurrentcisplatin chemotherapy. 
They had 3 CT guided individualised fractions of HDR 
brachytherapyaiming for a d90 >80Gy whilst respecting the 
published OARs dose constraints.These were compared with 
plans generated using the 3 CT plans for each patientto 
deliver a prescription of 7Gy to point A. The plans were 
compared in termsof the d90 to the HRCTV, v100 receiving 7 
Gy/ fraction, and the 2cc doses tobladder, rectum, sigmoid, 
small bowel and GI total. We also compared the d90per cm3 
of HRCTV as a surrogate of treatment delivery efficiency. 
Thepaired t-test (T) and pearson correlation coefficient (r) 
were used with2-tailed significance testing level of 0.05. 
Results: A total of 90 individualised plans were compared 
with 90 plans using point A prescription. The median HRCTV 
volume was 30.7cm3(20.1 – 72.4cm3), the total combined 
doses to point A for eachtechnique were comparable with a 
median dose of 75Gy for individualised planning and 73.6Gy 
for plans prescribed to point A. Descriptive data 
comparingthe 2 plans is in table 1: 
 
 
There was a statistically significant difference in the d90 
doses achieved by individualised planning compared to 
prescribing to point A,also only 4 (13%) cases using IGBTfailed 
to achieve a dose of >80Gy compared to 19 cases (63%). 
Although the median doses to the OARs were higher for 
individualised plans, this is contrasted by the number of 
cases who would have received clinically significant doses 
above the accepted dose constraints when prescribing to 
point A, where 2 cases would have received doses of 88.4 Gy 
and 90.9 Gy to the small bowel for a non-individualised plan. 
When looking at the impact of the HRCTV volume on the dose 
delivered to the tumour there was a negative correlation for 
both techniques. There was a stronger association for point A 
prescribing(r=-0.87; p<0.0001) compared to individualised 
planning (r=-0.52;p<0.003). Conforming the dose to the 
tumour volume and shape appears to mitigate for the 
negative effect of large HRCTV volumes. 
Conclusions: Individualised treatment planning for each 
brachytherapyfraction using CT scans allows an increase in 
the number of patients achievinga d90 of >80Gy whilst 
staying within the OARs dose constraints. Prescribingto point 
A without conforming the dose withimage guidance can result 
in a number of patients receiving clinicallysignificant 
overdoses to the OARs with most likely serious long term 
toxicity. 
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Purpose/Objective: To assess the impact of dose constraints 
on the clinical outcome in radio(chemo)therapy and MRI 
based image-guided adaptive brachytherapy (IGABT) for 
cervical cancer. 
Materials and Methods: Our study population consists of 225 
consecutive cervical cancer patients (FIGO stages IB - IVA) 
treated between 1998 – 2008 by external beam radiotherapy 
(EBRT) +/- chemotherapy and IGABT. For this retrospective 
study patients were stratified into two treatment groups: 
Group 1 (optimal treatment): all dose constraints fulfilled. 
Group 2 (suboptimal treatment): one or more dose 
constraints not fulfilled. The following dose constraints (EBRT 
+ brachytherapy dose) were applied: CTVHR D90 ≥85 Gy, D2cc 
rectum < 70 Gy, D2cc bladder <90 Gy. All doses were 
calculated by summation of the dose of all EBRT and 
brachytherapy fractions using the EQD2 model (α/β=10 Gy for 
target volume and α/β =3 Gy for OARs). Differences in event 
free interval [local tumor control and grade 4 toxicity 
(surgery necessary) according to LENT-SOMA score] were 
compared between the two treatment groups. 
Results: Optimal treatment received 77 (34%) and suboptimal 
148 (66%) of the patients. The mean follow-up in group 1 and 
group 2 was 54 and 49 months, respectively. FIGO stage in 
group 1 versus group 2 was: stage I 14 (18%) vs. 11 (7%), p= 
0.015, stage II 49 (64%) vs. 88 (60%), p= 0.545, stage III 14 
(18%) vs. 39 (26%), p= 0.172 and stage IV 0 (0%) vs. 10 (7%), 
p=0.020. There was a significant difference in the volume of 
HRCTV between the two groups (Group 1 vs. group 2: 34.2 
cm³ vs. 47.8 cm³, p=0.001).  
Five-year local recurrence free interval was 92.8% in group 1 
and 80.8% in group 2 (p=0.028). Grade 4 rectal toxicity was 
observed in 2 cases in group 1 and 1 case in group 2. Grade 4 
bladder toxicity was observed in 0 cases in group 1 and 2 
cases in group 2. Five-year event free interval (local 
recurrence or G4 toxicity) in group 1 and 2 was 90 % and 79% 
respectively (p=0.056). 
